Poster



Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) by composite physiologic index (CPI) at baseline American Thoracic Society (ATS) International Conference May 13-18, 2022 SC-US-74357

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) by composite physiologic index (CPI) at baseline

Athol U Wells,¹ Kristin B Highland,² Sven Gläser,³ Hilario Nunes,⁴ Jin Woo Song,⁵ Wim A Wuyts,⁶ Christian Stock,⁷ Margarida Alves,⁸ Maria Padilla⁹ on behalf of the SENSCIS trial investigators

¹National Institute for Health Research Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust, London, UK; ²Cleveland Clinic, Cleveland, OH, USA; ³Department of Internal Medicine - Pneumology, Vivantes Klinikum Spandau, Berlin, Germany; ⁴Department of Pulmonology, Hôpital Avicenne, APHP, Bobigny, France; ⁵Department of Pulmonary and Critical Care Medicine, Asan Medical Center, Seoul, South Korea; ⁶Department of Pulmonary Medicine, University Hospitals Leuven, Leuven, Belgium; ⁷Boehringer Ingelheim am Rhein, Germany; ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany; ⁹Icahn School of Medicine at Mount Sinai, New York, NY, USA.

INTRODUCTION

- The composite physiologic index (CPI) is a measure of the severity of pulmonary fibrosis, calculated based on per cent predicted values for DLco, FVC and FEV₁.¹ A higher score on the CPI has been associated with worse prognosis in patients with various ILDs.¹⁻⁵
- In the SENSCIS trial in patients with SSc-ILD, nintedanib reduced the rate of decline in FVC (mL/year) over 52 weeks by 44% compared with placebo.⁶

AIM

• To assess the effect of nintedanib in subgroups based on CPI at baseline in the SENSCIS trial.

METHODS

Trial design⁶

- Patients had SSc with first non-Raynaud symptom in the prior \leq 7 years, extent of fibrotic ILD on HRCT \geq 10%, FVC \geq 40% predicted, DLco 30–89% predicted.
- Patients taking prednisone ≤10 mg/day and/or stable therapy with mycophenolate or methotrexate for ≥6 months were allowed to participate.
- Patients were randomized to receive nintedanib or placebo.

Analyses

CPI was calculated as:1

91.0 – (0.65 × DLco % predicted) – (0.53 × FVC % predicted) + (0.34 × FEV, % predicted)

- In *post-hoc* analyses, we analyzed the following outcomes over 52 weeks in subgroups by baseline CPI \leq 45 vs >45: – rate of decline in FVC (mL/year)
- time to absolute decline in FVC ≥10% predicted or death
- proportions of patients with absolute declines in FVC % predicted >5% and >10% and relative declines in FVC (mL) >5% and >10% (with missing values at week 52 imputed using a worst value carried forward approach)
- time to absolute decline in FVC ≥10% predicted or death
- Interaction p-values were calculated to assess potential heterogeneity in the effect of nintedanib versus placebo between the subgroups.

CONCLUSIONS

- In the SENSCIS trial in patients with SSc-ILD, approximately half of the patients had a CPI >45 at baseline.
- The rate of FVC decline over 52 weeks was numerically greater in patients with CPI >45 than ≤45 in both the nintedanib and placebo groups.
- The effect of nintedanib vs placebo on reducing the rate of FVC decline was numerically more pronounced in patients with CPI >45 than ≤45, but no statistically significant heterogeneity was detected between these subgroups.

Scan QR code or visit URL for a device-friendly version of this poster including a voiceover from the lead author.

https://www.usscicomms.com/respiratory/ATS2022/Wells/

Scan QR code or visit URL for a webpage featuring BI-supported publications at ATS 2022.


https://www.usscicomms.com/respiratory/ATS2022







RI 1. 2. 3. 4. 5. 6.



REFERENCES

- . Wells AU et al. Am J Respir Crit Care Med 2003;167:962–969.
- Ryerson CJ et al. Chest 2015;148:1268–1275.
 Nurmi HM et al. BMC Pulm Med 2017;17:16.
- Nurmi HM et al. BMC Pulm Med 2017;17: 4. Jacob J et al. Respir Med 2017;130:43–51.
- Jacob J et al. Respir Med 2017;130:43–51 Jacob] et al. BMC Pulm Med 2017;17:81.
- Jacob J et al. BMC Pulm Med 2017;17:81.
 Distler O et al. N Engl J Med 2019;380:2518–2528.
- Distier O et al. N Engl J Med 2019;380:2518–2528.

ACKNOWLEDGEMENTS AND DISCLOSURES The SENSCIS trial was supported by Boehringer Ingelheim International GmbH (BI). The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors did not receive payment for the development of this poster. Elizabeth Ng of FleishmanHillard, London, UK, provided editorial and formatting assistance, which was contracted and funded by BI. BI was given the opportunity to review the poster for medical and scientific accuracy as well as intellectual property considerations. Athol Wells has received fees from Blade Therapeutics, BI, Roche. Maria Padilla has received grants from BI and fees from BI and Roche/Genentech.